Form 6-K Telix Pharmaceuticals For: Sep 14

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 10/20/2026

1. NVDA
2. SPY
3. EYPT
4. CRWV
5. AMZN

6. META
7. TSLA
8. IRON
9. SPCX
10. STLD

September 14, 2026 4:53 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of September, 2026

Commission File Number: 001-42128

Telix Pharmaceuticals Limited

(Translation of registrant’s name into English)

55 Flemington Road

North Melbourne, Victoria 3051, Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or

Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On September 14, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement

with the Australian Securities Exchange titled “FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara,”

a copy of which is attached to this Form 6-K as Exhibit 99.1.


99.1	Press release – September 14, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this

report to be signed on its behalf by the undersigned, thereunto duly authorized.



		Telix Pharmaceuticals Limited

Date :	September 14, 2026	By:	/s/ Christian Krautkramer
			Name: Christian Krautkramer
			Title: Group General Counsel

ATTACHMENTS / EXHIBITS

EX-99.1

SEC Filings

Sign up for StreetInsider Free!

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!